title: One year of clinical experience in postdilution hemofiltration with online reinfusion of regenerated ultrafiltrate.
abstract: OBJECTIVE
  Hemofiltrate reinfusion (HFR) is characterized by the use of regenerated ultrafiltrate as replacement fluid. We set up a new technique, postdilution HFR (PD-HFR), aiming at increasing purification efficiency, treatment tolerance and at reducing inflammatory states.
  
  
  METHODS
  We performed PD-HFR in 6 uremic patients during 1 year. Dialysis efficacy, dialyzer blood loss and the behavior of cytokines were evaluated.
  
  
  RESULTS
  No pyrogenic reactions or other adverse events were recorded. Treatment tolerance was excellent. We observed high urea extraction rates and optimal Kt/V values, high beta2-microglobulin (beta2m) extraction rates and a decrease in dialyzer blood loss; also IL-6 and TNF-alpha decreased significantly.
  
  
  CONCLUSIONS
  Inversion of the standard HFR configuration has allowed us to improve the removal of both urea and beta2m, and to decrease dialyzer blood loss, with an optimal tolerance. Moreover, the decrease in cytokine levels might attenuate the uremic microinflammatory state.
authors.affiliation: Nephrology and Dialysis Department, S. Eugenio Hospital, Rome, Italy.
authors.forename: Carlo
authors.initials: C
authors.lastname: Meloni
authors.forename: Paolo M
authors.initials: PM
authors.lastname: Ghezzi
authors.forename: Silvia
authors.initials: S
authors.lastname: Cipriani
authors.forename: Sandro
authors.initials: S
authors.lastname: Petroni
authors.forename: Giovanni
authors.initials: G
authors.lastname: Del Poeta
authors.forename: Bernardo
authors.initials: B
authors.lastname: Rossini
authors.forename: Valeria
authors.initials: V
authors.lastname: Rossi
authors.forename: Gabriele
authors.initials: G
authors.lastname: Recino
authors.forename: Giovanna
authors.initials: G
authors.lastname: Suppo
authors.forename: Annalisa
authors.initials: A
authors.lastname: Cecilia
authors.forename: Carlo U
authors.initials: CU
authors.lastname: Casciani
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D017583:Hemodiafiltration / Q000379:methods*; D015312:Hemodialysis Solutions / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D015312:Hemodialysis Solutions